https://healthcare-digital.com/news/novo-hengrui-agree-us-2-6bn-deal-for-weekly-glp1-gip-pillhttps://assets.bizclikmedia.net/1200/0797031077fc180c3d4f30e3415dd030:058da90fefae9e64829b78a8cba5f8f0/novo-nordisk-logo.jpeg.jpgThe Novo-Hengrui deal is another indication that the GLP-1 market is moving towards a new generation of treatments in which oral medicines will likely play a much greater role. Credit: NovoThe Novo-Hengrui deal is another indication that the GLP-1 market is moving towards a new generation of treatments in which oral medicines will likely play a much greater role. Credit: Novohttps://assets.bizclikmedia.net/1200/7360f4d90bab378ca688cb007001c9a3:f5edc4ace00f1030a7c65313bfa3b05e/1752075193789-e-1764201600-v-beta-t-ex-wl-ejd6ojyr7lcdnjkg5gfmu3i0sl1gtw6io0rgg.jpgMaziar Mike Doustdar, CEO Of Novo. Credit: Novo.Maziar Mike Doustdar, CEO Of Novo. Credit: Novo.https://assets.bizclikmedia.net/1200/d94c7ef96369535fe805270502ec867b:2400d063eddfc2db504d25c9cac13419/martin-holst-lange.jpgMartin Holst Lange, Executive Vice President of R&D & Chief Scientific Officer at Novo. Credit: LinkedInMartin Holst Lange, Executive Vice President of R&D & Chief Scientific Officer at Novo. Credit: LinkedIn